Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aim: To evaluate the pharmacological characteristics of faster‐acting insulin aspart (faster aspart) compared with insulin aspart ( IAsp ) during continuous subcutaneous insulin infusion ( CSII ). Methods: In this randomized, double‐blind, crossover trial, 48 men and women aged 18 to 64 years with type 1 diabetes mellitus ( T1DM ) received faster aspart and IAsp as a 0.15 U/kg bolus dose via CSII , on top of a basal rate (0.02 U/kg/h), in a glucose clamp setting (target 5.5 mmol/L). Results: After a CSII bolus dose, the pharmacokinetic/pharmacodynamic profiles for faster aspart were left‐shifted compared with those for IAsp . For faster aspart vs IAsp , the early glucose‐lowering effect (area under the curve for glucose infusion rate [ GIR ] 0‐30min ) was approximately 2‐fold higher (least squares means 24.9 vs 11.4 mg/kg; estimated ratio faster aspart/ IAsp 2.18, 95% confidence interval [CI] [1.33; 5.04]; P = .002), onset of glucose‐lowering effect (time to early 50% of maximum GIR ) occurred 11.1 minutes earlier (41.1 vs 52.3 minutes; 95% CI faster aspart – IAsp [−15.4; −6.9]; P <.001), and offset of glucose‐lowering effect (time to late 50% of maximum GIR ) occurred 24.0 minutes earlier (214.7 vs 238.7 minutes; 95% CI [−38.9; −9.1]; P =.002). Likewise, significantly greater early exposure and significantly earlier onset and offset of exposure were observed for faster aspart vs IAsp . Faster aspart and IAsp were both well tolerated. Conclusions: In patients with T1DM using CSII , faster aspart better mimics the endogenous prandial insulin secretion and action than does IAsp . Faster aspart therefore has the potential to provide clinical benefits over current rapid‐acting insulins in the insulin pump setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Bell, K. J., Smart, C. E., Steil, G. M., Brand-Miller, J. C., King, B., & Wolpert, H. A. (2015) · Diabetes Care · doi:10.2337/dc15-0100 · Cited by 390
Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes
Woerle, H. J., Neumann, C., Zschau, S., Tenner, S., Irsigler, A., Schirra, J., Gerich, J. E., & Göke, B. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.11.011 · Cited by 316
Riddle, M., Umpierrez, G., DiGenio, A., Zhou, R., & Rosenstock, J. (2011) · Diabetes Care · doi:10.2337/dc11-0632 · Cited by 219
Home, P. D. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01580.x · Cited by 212
Bode, B. W. (2011) · Endocrine Practice · doi:10.4158/ep10260.ra · Cited by 56
Moving toward the ideal insulin for insulin pumps
Cengiz, E., Bode, B., Van Name, M., & Tamborlane, W. V. (2016) · Expert Review of Medical Devices · doi:10.1586/17434440.2016.1109442 · Cited by 38 · cited 2×
“post-meal hypoglycaemia, and could also be a key factor in improving the performance of closed-loop, artificial pancreas systems.(9) Faster-acting insulin aspart (faster aspart) is insulin aspart in a”
Background
Cited by
Insulin analogues in type 1 diabetes mellitus: Getting better all the time
Mathieu, C., Gillard, P., & Benhalima, K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.39 · Cited by 248
Mann, J. L., Maikawa, C. L., Smith, A. A. A., Grosskopf, A. K., Baker, S. W., Roth, G. A., Meis, C. M., Gale, E. C., Liong, C. S., Correa, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba6676 · Cited by 62
Heise, T., Meiffren, G., Alluis, B., Seroussi, C., Ranson, A., Arrubla, J., Correia, J., Gaudier, M., Soula, O., Soula, R., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13621 · Cited by 40
Self-citationEffect of Afrezza on Glucose Dynamics During HCL Treatment
Galderisi, A., Cohen, N., Calhoun, P., Kraemer, K., Breton, M., Weinzimer, S., & Cengiz, E. (2020) · Diabetes Care · doi:10.2337/dc20-0091 · Cited by 32
“Faster-acting aspart insulin, a modified formulation of aspart insulin, has been shown to have faster appearance in circulation and greater glucoselowering effect during the first 2 h from administrationthanaspart(12,13).”
BackgroundNørgaard, K., Sukumar, N., Rafnsson, S. B., & Saravanan, P. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0411-7 · Cited by 26
Metadata
- Authors
- Heise, T., Zijlstra, E., Nosek, L., Rikte, T., & Haahr, H.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-11-14
- Volume
- 19
- Issue
- 2
- Pages
- 208-215
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2529414368
- Cited by
- 78
- References
- 9
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial. https://app.cochat.ai/papers/10.1111/dom.12803
- The paper
- Heise, T., Zijlstra, E., Nosek, L., Rikte, T., & Haahr, H. (2017). Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12803
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.